支氣管擴張劑全球市場規模、佔有率、成長分析、按藥物類型、按給藥途徑分類 - 產業預測 (2024-2031)

Global Bronchodilators Market Size, Share, Growth Analysis, By Drug Type(Beta2-Adrenergic Agonists, Sympathomimetics), By Route of Administration(Oral, Injection) - Industry Forecast 2024-2031

出版日期: 2024年03月11日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球支氣管擴張劑市場規模為221.9億美元，從2023年的234.8億美元成長到2031年的368.6億美元，預測期（2024-2031）預計複合年成長率為5.8%。

由於支氣管炎、氣喘和慢性阻塞性肺病（COPD）等呼吸系統疾病的盛行率不斷增加，支氣管擴張劑市場正在顯著擴大。支氣管擴張劑藥物可以擴張和放鬆肺部氣道，使呼吸更容易。由於各種呼吸系統疾病的全球負擔日益增加以及環境變數和生活方式的變化，對支氣管擴張劑的需求正在增加。市面上有兩種類型的支氣管擴張劑：短效和長效，每種都為患者提供不同的用途。長效支氣管擴張劑為慢性治療提供長期效果，而短效支氣管擴張劑為急性呼吸道疾病提供立即緩解。由於呼吸道疾病的高發病率、發達的醫療保健系統和不斷提高的意識，北美和歐洲佔據了主要市場佔有率。由於人口稠密地區的污染水平上升和生活方式的改變，亞太地區正在成為一個有價值的市場。此外，乾粉吸入器和定量吸入器等吸入裝置的改進提高了患者的依從性和藥物輸送功效。由於呼吸道疾病盛行率上升，支氣管擴張劑市場預計將進一步成長。這種成長是由持續的研究、創新的藥物配方和製藥行業內巧妙的合作夥伴關係所推動的。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2021年）
主要市場參與者所採取的策略
關鍵成功策略
近期市集活動
主要企業市場佔有率（2021年）

主要企業簡介

GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Novartis
Merck & Co.
Mylan NV
Sunovion Pharmaceuticals
Cipla
Vectura Group
Chiesi Farmaceutici
Mundipharma
Perrigo
Orion Corporation
Almirall

簡介目錄

Product Code: SQMIG35I2257

Global Bronchodilators Market size was valued at USD 22.19 billion in 2022 and is poised to grow from USD 23.48 billion in 2023 to USD 36.86 billion by 2031, growing at a CAGR of 5.8% during the forecast period (2024-2031).

The market for bronchodilators is expanding significantly as a result of the increased incidence of respiratory conditions such bronchitis, asthma, and chronic obstructive pulmonary disease (COPD). Medication known as a bronchodilator widens and relaxes the lungs' airways to facilitate breathing. The demand for bronchodilator drugs is being driven by the rising global burden of various respiratory illnesses, as well as by changing environmental variables and lifestyles. The two types of bronchodilators available on the market are short-acting and long-acting, with each serving a distinct purpose for patients. While long-acting bronchodilators give prolonged benefits for chronic treatment, short-acting bronchodilators offer immediate relief during acute respiratory issues. Due to a high incidence of respiratory illnesses, a developed healthcare system, and growing awareness, North America and Europe control significant market shares. Because of rising pollution levels and changing lifestyles in densely populated areas, the Asia-Pacific region is becoming a valuable market. Furthermore, improvements in inhalation devices-like dry powder inhalers and metered-dose inhalers-are improving patient compliance and the effectiveness of medication delivery. The market for bronchodilators is expected to grow further as the prevalence of respiratory conditions rises. This growth will be fueled by ongoing research, creative medication formulations, and clever partnerships within the pharmaceutical sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bronchodilators Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bronchodilators Market Segmental Analysis

Based on Indication, Drug Type, Route of Administration, and Region, the global market for bronchodilators is divided into segments. The market is divided into categories based on indication, including asthma, chronic obstructive pulmonary disease (COPD), and others. The market is divided into four segments based on the kind of drug: combination bronchodilators, beta2-adrenergic antagonists, anticholinergic agents, and methylxanthines. The market is divided into oral, injection, and inhaler segments based on the route of administration. The market is divided into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa based on region.

Drivers of the Global Bronchodilators Market

The market for bronchodilators is mostly driven by the rising prevalence of respiratory conditions such bronchitis, asthma, and chronic obstructive pulmonary disease (COPD). Effective bronchodilator drugs are required for both disease management and symptom alleviation because to the increasing global burden of these illnesses.

Restraints in the Global Bronchodilators Market

Certain bronchodilators, especially those that are breathed, may cause side effects such headaches, tremors, and elevated heart rate. These side effects may cause patients to stop using the medication consistently or to stop following their treatment plans.

Market Trends of the Global Bronchodilators Market

One essential part of administering bronchodilators is using inhalation devices. Advanced inhaler technologies, such smart inhalers and digital monitoring systems, are becoming more and more popular in the market. These developments improve treatment adherence and illness management by providing real-time drug consumption monitoring and feedback to patients and medical providers.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Bronchodilators Market by Drug Type

Market Overview
Beta2-Adrenergic Agonists
Sympathomimetics
Anticholinergics
Phosphodiesterase Inhibitor
and Combination Drugs.

Global Bronchodilators Market by Route of Administration

Market Overview
Oral
Injection
and Inhaler.

Global Bronchodilators Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sunovion Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vectura Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chiesi Farmaceutici
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mundipharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perrigo
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orion Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almirall
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments